Login to Your Account

Afinitor shown to delay tumor growth in HER2+ advanced breast cancer

By John Fox
Staff Writer

Tuesday, June 3, 2014

HONG KONG – Adding the oral molecular targeted therapy Afinitor (everolimus, Novartis AG) to conventional chemotherapy plus anti-HER2 treatment reduced the risk of progression of human epidermal growth factor receptor-2 (HER2)-positive advanced breast cancer resistant to Herceptin (trastuzumab, Roche AG) by 22 percent and may provide clues to the mechanisms underlying Herceptin resistance, researchers reported.

To continue reading subscribe now to Science News

Learn More about Science News

Already a subscriber? Sign In or Buy now to activate your subscription